Drugs
Alpha-Beta Technology Inc., a company developing proprietary pharmaceutical products, reported a net loss of $6,329,779 for the second quarter of 1995, resulting in a loss of $0.54 per share. The significant loss was attributed to the expanded development and Phase III clinical trial of BETAFECTIN(R) PGG-glucan,
Drugs
IBAH, a leading provider of product development services to the pharmaceutical, biotechnology, and medical device industries, announced its financial results for the second quarter ended June 30, 1995. The Company reported a 42% increase in pro forma net revenues to $11.4 million, driven by significant growth in the European
Drugs
IVAX Corporation, a Miami-based holding company with subsidiaries in the personal care products, pharmaceuticals, and in vitro diagnostics industries, has announced the appointment of two new executives in key positions. Edward J. O'Brien has joined the company as Vice President of Human Resources, while Joseph C. Jones has
Drugs
Longs Drug Stores, a major provider of pharmacy services in the western United States, has announced the formation of a new subsidiary, Integrated Health Concepts (IHC), to enhance its position in the growing managed health care market. As part of its strategy to expand its pharmacy services, Longs has established
Pharmaceutical industry
McKesson Corp., the largest provider of pharmaceutical and health care products and services in North America, has successfully implemented one of the industry's largest data warehouses running on Pyramid's highly scalable enterprise servers. This strategic data warehouse will provide McKesson with a new level of business
Pharmaceutical industry
Developed to detect early signs of kidney impairment, the MICRAL(TM) urine dipstick test is poised to revolutionize the diagnostic process for kidney disease. Co-marketed by Boehringer Mannheim Pharmaceuticals Corporation (BMPC) and Boehringer Mannheim Corporation -- Diabetes Care Division (BMC-DC), this innovative product will leverage the strengths of both companies
Drugs
Therapeutic Discovery Corporation (TDC), a biotechnology company based in Palo Alto, California, has announced its second-quarter financial results for 1995. The company reported a net loss of $11.1 million, or $1.44 per common share, for the quarter ended June 30, 1995. This compares to a net loss of
Drugs
Ethical Holdings plc, a specialist drug delivery group, has reported a significant increase in revenues for the third quarter of 1995, with a loss of £1.26 million. The Group's revenues increased by 32 percent to £2.71 million from £2.06 million in the same period in
Pharmaceutical industry
Merck & Co. Inc. announced the signing of a definitive agreement to divest its ownership of Medco Behavioral Care Corp. (MBC) to MBC management and Kohlberg Kravis Roberts & Co. (KKR) for $340 million. The transaction reflects Merck's intention to focus its resources on its core human and
Pharmaceutical industry
Sandoz has entered into a definitive merger agreement with Genetic Therapy, Inc. (Nasdaq: GTII) to acquire the gene therapy research and development organization in a cash tender offer at USD 21.00 per share. The acquisition will enable Sandoz to advance its position in gene therapy technology and solidify its
Drugs
Hoechst AG, a major German chemical company, has announced plans to reduce its workforce in its pharmaceutical division by about 8,000 jobs by the end of 1997. This move is part of the company's efforts to integrate its pharmaceutical activities, leading to "synergies and overlaps."
Pharmaceutical industry
CIBA Ltd., a multinational pharmaceutical company, has selected the Documentum Enterprise Document Management System (EDMS) as its corporate document management standard. This strategic move aims to accelerate and improve business processes, particularly in research, development, new drug submissions, production, sales, and marketing. The Documentum EDMS will enable CIBA's
